Evaluation of anti-L-asparaginase antibody and difference of antibody production in each patient

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06726
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: National Institute of Health Sciences
• Principal Investigator: Tanaka Yoichi 国立医薬品食品衛生研究所, 医薬安全科学部, 主任研究官 (40525341)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: アスパラギナーゼ / 抗体 / IgG / IgE / 過敏症 / 小児血液がん

Outline of Final Research Achievements

The method was established to quantify antibody titers of anti-asparaginase antibodies (IgG and IgE) in serum by electrochemiluminescence, based on serum samples provided by pediatric hematological cancer patients treated with L-asparaginase. It was found that the titers of anti-asparaginase IgG and IgE antibodies were significantly higher in patients who had experienced hypersensitivity to asparaginase than in those who had not experienced hypersensitivity to asparaginase. ROC analysis of hypersensitivity development revealed that the ROAUC for IgG and IgE was about 0.8, suggesting that hypersensitivity development could be diagnosed with high sensitivity. For anti-asparaginase IgE antibody, the cellular responsiveness of the antibody was evaluated by the IgE-Crosslinking-induced Luciferase Expression method, but no response was confirmed in patient serum.

Free Research Field

医療系薬学

Academic Significance and Societal Importance of the Research Achievements

アスパラギナーゼ投与に伴う過敏症を経験した患者において、抗アスパラギナーゼ抗体の抗体価が高値を示す事から、アスパラギナーゼ投与時に発現した症状が過敏反応かを判別する場合に抗体価を指標とする事ができる可能性がある。また、IgGまたはIgE抗体が高値になる事と過敏症の発現について更なる検討を行うことで、メカニズムの解明につながると考えられる。